Last Update 17 May 26

Fair value Decreased 0.58%

UTHR: Soft Mist Inhaler Shift Will Pressure Pulmonary Hypertension Expectations

Narrative Update

The updated analyst price target for United Therapeutics has edged down by $3 to $516, as analysts factor in a mix of slightly lower projected revenue growth, higher expected profit margins, and a reduced future P/E multiple, following a wave of recent target hikes and one trim across the Street.

Analyst Commentary

Recent research on United Therapeutics is mixed. Several firms have raised price targets and highlighted potential upside tied to pulmonary hypertension and idiopathic pulmonary fibrosis programs, while a smaller group of bearish analysts has stressed execution risks, product mix uncertainty, and questions around sustainability of current expectations.

Bullish analysts are generally focused on late stage data for ralinepag and Tyvaso in idiopathic pulmonary fibrosis, as well as the planned launch of a soft mist treprostinil inhaler in 2027, pending regulatory approvals. They see these programs as important for reinforcing the pulmonary arterial hypertension franchise and for broadening the product base if clinical and regulatory milestones are achieved.

At the same time, developments around United Therapeutics' soft mist inhaler have had a ripple effect on partners and competitors, particularly in relation to Tyvaso DPI royalties and potential future device preferences. That has brought more attention to how United Therapeutics balances its different inhaled treprostinil formulations and manages its broader pulmonary portfolio over the coming years.

Across the recent research, there is also discussion of revenue and earnings trends. Some analysts point to a "modest" revenue shortfall and mixed quarterly results, with commentary that the stock reaction was driven more by product announcements and trial expectations than by the reported numbers themselves. Others emphasize that upcoming trial readouts and potential product launches are key checkpoints for whether United Therapeutics can meet its longer term revenue goals.

Overall, the Street view reflects both optimism around the clinical pipeline and caution around product cannibalization, royalty disputes, and the timing and outcome of major trials. For investors, the key question is how much of this future optionality is already embedded in the current valuation versus what still depends on data and regulatory outcomes that are not yet known.

Bearish Takeaways

Bearish analysts point to a recent price target cut of US$3 and an Equal Weight stance as a sign that, after a strong run of upward revisions, some on the Street see risk that expectations for revenue trajectory and margins might already be full in the current P/E multiple.
Multiple reports flag that the soft mist treprostinil inhaler could shift volume away from Tyvaso DPI and related royalties, raising concerns about product mix, partner relationships, and how much incremental value actually accrues to United Therapeutics versus creating volatility for its ecosystem.
The commentary around a "modest" revenue miss and mixed quarterly results, including references to a Q1 growth callout that implies a 2026 revenue re basing, has fed into worries that top line trends may not track earlier expectations without clean execution on upcoming launches.
Some bearish analysts stress that management's long term revenue ambitions, including a stated US$4b run rate target by 2H27, still depend on several clinical, regulatory, and commercial milestones. This leaves room for disappointment if timelines slip or new products ramp more slowly than hoped.

What's in the News

FDA cleared United Therapeutics to begin the EXPRESS clinical study of UHeart, an investigational pig derived xenoheart with 10 gene edits, in a phase 1/2/3 trial initially enrolling up to two end stage heart failure participants. The study has the potential for expansion to support a future BLA filing (Key Developments).
The company received FDA Regenerative Medicine Advanced Therapy designation for miroliverELAP, an external liver assist product using a bioengineered porcine liver seeded with human cells, following positive phase 1 data in acute liver failure patients (Key Developments).
Nebulized Tyvaso met the primary endpoint in the phase 3 TETON 1 IPF study. Integrated TETON 1 and TETON 2 analyses showed statistically significant treatment effects on lung function and several secondary measures, with a supplemental NDA for an IPF label expansion planned for submission to the FDA by the end of summer 2026 (Key Developments).
The long term phase 3 ADVANCE OUTCOMES trial of ralinepag in pulmonary arterial hypertension met its primary endpoint, reducing the risk of clinical worsening events compared with placebo and showing statistically significant improvements in key secondary measures. An NDA submission to the FDA is targeted for the second half of 2026 (Key Developments).
The Board authorized a new share repurchase program of up to US$2b for one year. The company reported completing a US$1.5b tranche, repurchasing 2,164,459 shares, equal to 4.94% of shares, under the buyback announced on March 9, 2026 (Key Developments).

Valuation Changes

Fair Value: updated to $516, down slightly from $519, reflecting a modest trim to the underlying valuation estimate.
Discount Rate: adjusted slightly lower to 7.11% from 7.14%, a small change in the rate used to discount future cash flows.
Revenue Growth: projected revenue growth has fallen significantly to 1.18% from 3.53%, indicating a more conservative top line outlook in the model.
Net Profit Margin: projected net profit margin has risen to 42.93% from 39.02%, implying higher expected profitability on each dollar of sales.
Future P/E: the assumed future P/E multiple has declined to 15.75x from 18.52x, suggesting a lower valuation multiple applied to expected earnings.

1 view

Key Takeaways

Heavy dependence on a few core drugs heightens risk from patent expirations, increasing vulnerability to revenue declines and competition from generics.
Significant investments in novel therapies face technical and regulatory uncertainties, with potential delays and high costs threatening profitability and future earnings.
Strong core product performance, promising late-stage pipeline, and investment in organ technologies position United Therapeutics for diversified long-term growth and resilience against competition.

Catalysts

About United Therapeutics

A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.What are the underlying business or industry changes driving this perspective?

While United Therapeutics has experienced sustained revenue growth fueled by Tyvaso DPI and a concentrated portfolio, this heavy reliance on a small number of key drugs, particularly Tyvaso and Remodulin, exposes the company to severe patent expiration and generic/biosimilar risk over the long term, which could trigger sharp revenue declines once exclusivity erodes.
Despite the company's aggressive investment in advanced organ manufacturing and xenotransplantation, these pipeline projects face enormous technical, regulatory, and operational uncertainty, with the potential for multi-year clinical setbacks and high R&D costs to severely pressure net margins and delay any meaningful contribution to earnings.
The anticipated growth in rare and chronic disease therapies may be constrained as demographic trends shift, including slowing addressable patient pool growth due to plateauing chronic disease rates and aging in some developed markets, ultimately limiting future revenue expansion opportunities.
As healthcare payor consolidation intensifies and governments worldwide escalate scrutiny on high specialty drug pricing, United Therapeutics is likely to encounter downward pressure on prices and reimbursement, compressing both gross and net margins across its product suite and making profitability increasingly volatile and uncertain.
The expected acceleration in biosimilar and generic competition, amplified by regulatory changes favoring faster market entry for alternatives, threatens to shorten the revenue lifecycle and diminish peak sales for United Therapeutics' existing and future therapies, heightening earnings risk and challenging the company's long-term financial resilience.

United Therapeutics Earnings and Revenue Growth

United Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on United Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming United Therapeutics's revenue will grow by 1.2% annually over the next 3 years.
The bearish analysts assume that profit margins will increase from 40.6% today to 42.9% in 3 years time.
The bearish analysts expect earnings to reach $1.4 billion (and earnings per share of $26.7) by about May 2029, up from $1.3 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $2.2 billion.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 15.8x on those 2029 earnings, down from 18.7x today. This future PE is lower than the current PE for the US Biotechs industry at 17.2x.
The bearish analysts expect the number of shares outstanding to decline by 6.15% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

United Therapeutics has demonstrated twelve consecutive quarters of double-digit year-over-year revenue growth, supported by continued strong uptake across its core commercial products, which suggests robust demand and could drive long-term revenue and earnings expansion.
The company's foundation is anchored by the Tyvaso franchise, including Tyvaso DPI, which continues to achieve record shipments, maintain strong market fundamentals, and shows resilience even in the face of new competing products, indicating ongoing pricing power and stable gross margins.
The late-stage pipeline, including pivotal TETON studies in idiopathic pulmonary fibrosis (IPF) and the ADVANCE OUTCOMES study in PAH, presents multiple large potential catalysts; success in these trials could significantly expand addressable markets and increase future revenue streams.
United Therapeutics is actively investing in innovative growth platforms such as organ manufacturing and xenotransplantation, offering the possibility for entirely new multi-billion dollar revenue streams that diversify the business beyond current core therapies, which could meaningfully increase future earnings.
The company maintains a robust balance sheet with annual operating cash flow near $1.5 billion and a newly authorized $1 billion share repurchase program, which signals confidence from the board in both near
and long-term business prospects and could drive higher earnings per share.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for United Therapeutics is $516.0, which represents up to two standard deviations below the consensus price target of $663.58. This valuation is based on what can be assumed as the expectations of United Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $750.0, and the most bearish reporting a price target of just $516.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $3.3 billion, earnings will come to $1.4 billion, and it would be trading on a PE ratio of 15.8x, assuming you use a discount rate of 7.1%.
Given the current share price of $568.58, the analyst price target of $516.0 is 10.2% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on United Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Patent Expirations And Biosimilar Pressures Will Diminish Value